SPTX (Seaport Therapeutics) EBITDA Margin %: 0.00% (As of Dec. 2025)


SPTX Seaport Therapeutics Inc SPTX
11 GF Score
Price $21.43
! 1 Warning Sign
View Full Analysis

What is Seaport Therapeutics EBITDA Margin %?

Seaport Therapeutics SPTX +10.37% 11 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates SPTX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, Seaport Therapeutics ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Seaport Therapeutics's EBITDA for the six months ended in Dec. 2025 was $-85.89 Mil. Seaport Therapeutics's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Seaport Therapeutics's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Seaport Therapeutics  (NAS:SPTX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Seaport Therapeutics EBITDA Margin % Related Terms

Seaport Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Seaport Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seaport Therapeutics EBITDA Margin % Chart

Seaport Therapeutics Annual Data
Trend Dec24 Dec25
EBITDA Margin %
0.00 0.00

Seaport Therapeutics Semi-Annual Data
Dec24 Dec25
EBITDA Margin % 0.00 0.00

SPTX vs LXRX, DRTS, MGTX: EBITDA Margin % Comparison

For the Biotechnology subindustry, Seaport Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seaport Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seaport Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Seaport Therapeutics's EBITDA Margin % falls into.


SPTX
11GF Score
Seaport Therapeutics Inc SPTX
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seaport Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Seaport Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-85.889/0
= %

Seaport Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-85.889/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Seaport Therapeutics (SPTX) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Seaport Therapeutics and its competitors. According to the industry distribution chart, Seaport Therapeutics ranks #999999 out of 944 companies in the Biotechnology industry.
Is Seaport Therapeutics' EBITDA Margin % too high?
Seaport Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Seaport Therapeutics ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Seaport Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Seaport Therapeutics' EBITDA Margin % compare to LXRX and DRTS?
According to the Biotechnology industry distribution chart, Seaport Therapeutics ranks #999999 out of 944 companies for EBITDA Margin %. This places Seaport Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Seaport Therapeutics and its competitors. Seaport Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seaport Therapeutics stock overvalued right now?
Seaport Therapeutics (SPTX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Seaport Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Seaport Therapeutics (SPTX), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seaport Therapeutics Business Description

Address 101 Seaport Boulevard, Floor 12, Boston, MA, USA, 02210
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
11GF Score

Get the complete analysis for SPTX

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.43
Price